Located at the Global Cardiovascular Innovation Center in Cleveland, Ohio, scientists of the Cleveland Cord Blood Center’s Research & Development Laboratory are conducting innovative research in the development of stem cell treatments to address unmet medical needs in patients suffering from Parkinson’s disease, diabetes, and those with wound healing issues.


The research team is exploring applying umbilical cord blood-derived induced regulatory T (iTreg) cells for the prevention and treatment of diabetic retinopathy. Cord blood induced iTreg cell injection shows promise by suppressing inflammatory and abnormal blood vessel formation caused by the disease, meaning a single injection might be sufficient rather than injections into the eye every 30 to 90 days as required by current treatment protocols. Learn more about this important research HERE.


CCBC researchers are spearheading the generation of special immune cells called ‘inducible T regulatory (iTreg) cells for pa­tients with immune disorders like Type 1 diabetes. The hope is that iTregs from cord blood will dampen the effects of diabetes in the pancreas, so the patient is not dependent on daily insulin injections. Learn more about our efforts to initiate breakthroughs HERE.


Early laboratory studies are inves­tigating stem cell therapy for patients with Parkinson’s disease. Researchers are investigating a cellular therapy-based treatment to support and regenerate special cells in the brain that produce dopamine, an important chemical that is decreased in the brain of Parkinson’s disease patients. Learn more about CCBC’s research into cell therapies for Parkinson’s disease HERE.


Studies are underway to devel­op novel, off-the-shelf wound healing products that support killing of bacteria, and treating patients with infected non-healing wounds. Learn more about research into cellular therapies for wound-healing applications HERE.